- Home
- HFRO vs CTNM Comparison
HFRO vs CTNM Comparison
Compare HFRO & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFRO
- CTNM
- Stock Information
- Founded
- HFRO 2000
- CTNM 2009
- Country
- HFRO United States
- CTNM United States
- Employees
- HFRO N/A
- CTNM N/A
- Industry
- HFRO Finance/Investors Services
- CTNM
- Sector
- HFRO Finance
- CTNM
- Exchange
- HFRO Nasdaq
- CTNM Nasdaq
- Market Cap
- HFRO 402.7M
- CTNM 453.0M
- IPO Year
- HFRO N/A
- CTNM 2024
- Fundamental
- Price
- HFRO $5.87
- CTNM $16.48
- Analyst Decision
- HFRO
- CTNM Strong Buy
- Analyst Count
- HFRO 0
- CTNM 3
- Target Price
- HFRO N/A
- CTNM $28.67
- AVG Volume (30 Days)
- HFRO 421.7K
- CTNM 103.0K
- Earning Date
- HFRO 01-01-0001
- CTNM 11-16-2024
- Dividend Yield
- HFRO 12.00%
- CTNM N/A
- EPS Growth
- HFRO N/A
- CTNM N/A
- EPS
- HFRO 1.23
- CTNM N/A
- Revenue
- HFRO $44,535,929.00
- CTNM N/A
- Revenue This Year
- HFRO N/A
- CTNM N/A
- Revenue Next Year
- HFRO N/A
- CTNM N/A
- P/E Ratio
- HFRO $5.50
- CTNM N/A
- Revenue Growth
- HFRO N/A
- CTNM N/A
- 52 Week Low
- HFRO $5.92
- CTNM $13.27
- 52 Week High
- HFRO $9.38
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- HFRO 35.00
- CTNM N/A
- Support Level
- HFRO $5.82
- CTNM N/A
- Resistance Level
- HFRO $6.24
- CTNM N/A
- Average True Range (ATR)
- HFRO 0.13
- CTNM 0.00
- MACD
- HFRO -0.04
- CTNM 0.00
- Stochastic Oscillator
- HFRO 10.42
- CTNM 0.00
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. The company's portfolio of investments includes different industry investments such as Financial, Communication Services, Energy, Healthcare, Materials, and others.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.